旨在每年筹集10亿美元的全球生物多样性基金"卡利基金"自2025年2月启动以来募资困难，截至COP17大会召开时仅获得7,085美元实际到账资金1。尽管大型制药公司从全球生物遗传信息中获利丰厚，但包括顶级药企在内的主要制药企业均未向该基金捐款1，被批评"不劳而获"地从自然中获利1。
根据零碳分析公司的研究，2025年全球顶级15家制药企业的利润约1610亿美元1。按照基金建议的捐献标准——利润的1%或营收的0.1%计算，这些企业本应捐献7.56亿美元1。然而，这些企业给股东的分红总额是建议捐献额的175倍1。截至周一，该基金仅收到来自三家小型私企的捐款：英国Prozomix公司5,000美元、英国TierraViva AI公司1,000美元和比利时E-Biom公司1,085美元1。基金资金中至少50%将用于原住民和当地社区确定的优先保护区域1。
The Kalihi Fund, a global initiative designed to raise $1 billion annually for biodiversity protection, has struggled dramatically since its launch in February 2025, attracting only $7,085 in actual funding by the time of COP17's opening on Monday.1 Major pharmaceutical companies have contributed nothing to the effort, drawing accusations that they are profiting from nature without shouldering responsibility for its preservation.1
The fund's shortfall is particularly striking given the pharmaceutical industry's dependence on global genetic resources to develop profitable medications.1 Research by Zero Carbon Analytics found that the world's top 15 pharmaceutical companies generated approximately $161 billion in profits in 2025, and by the fund's suggested contribution standard—1 percent of profits or 0.1 percent of revenue—these firms should have donated $756 million combined.1 Instead, the same companies distributed $132.3 billion to shareholders, a sum 175 times larger than what they were encouraged to contribute to biodiversity conservation.1
As of the conference's opening, the fund had received only $10,656 in total commitments, with actual disbursements limited to donations from three small enterprises: $5,000 from UK-based Prozomix, $1,000 from UK-based TierraViva AI, and $1,085 from Belgium's E-Biom.1 Industry representatives have pushed back against the fund's structure, arguing that the contribution requirements are poorly designed and duplicate existing legal frameworks.1 According to the fund's governance model, at least 50 percent of its resources are intended to support conservation priorities identified by indigenous and local communities.1
评论
还没有评论，欢迎留下第一条。